Tobetsa mona ho bonts'a lifolakha tsa HAO leqepheng lena mme u lefelle katleho feela

Litaba tsa mohala

Lintlha tse ncha mabapi le asthma e matla

ngotsoeng ke mohlophisi

Kajeno Amgen e phatlalalitse liphetho tsa tlhahlobo e kopaneng ea kamora hoc ea liteko tsa bohlokoa tsa NAVIGATOR Phase 3 le PATHWAY Phase 2b li bonts'itse TEZSPIRE™ (tezepelumab-ekko) e bonts'itse phokotso ea sekhahla sa selemo le selemo sa asthma exacerbation (AAER) ho pholletsa le lihlopha tse nyane tsa biomarker tsa bakuli ba asthma e matla. 1 Liphuputso tsena li tšehetsa karolo ea TEZSPIRE e le phekolo ea boemo ba pele bakeng sa batho ba bangata ba phelang le asthma e matla, ho sa tsotellehe maemo a biomarker.1           

Tlhahlobong e kopaneng, TEZSPIRE, ha e eketsoa ho maemo a tlhokomelo (SoC), e fokolitse ho mpefala ha asthma ho bakuli, ho sa tsotelehe lipalo tsa li-eosinophil tsa mali, ho bonts'a katleho e ts'oanang le 71% (≥300 lisele ka microliter), 48% (<300 lisele ka microliter) le 48% (<150 lisele ka microliter) ho fokotseha ha AAER ho feta libeke tsa 52, ha li bapisoa le placebo e kenyellelitsoeng ho SoC.1 Ka tlhahlobo e tšoanang, TEZSPIRE e boetse e bontšitse ntlafatso ho AAER ho bakuli ho sa tsotellehe hore na ho na le nitric oxide e nang le fractional exhaled nitric oxide. Boemo ba FeNO) le boemo ba ho kula ho feta libeke tse 52, ha li bapisoa le placebo.1

Ho phaella moo, tlhahlobong e boletsoeng esale pele ea lipatlisiso ho tsoa ho NAVIGATOR, TEZSPIRE e bontšitse katleho e tsitsitseng ho pholletsa le selemo ho sa tsotellehe nako ea selemo. 2% (hoetla) ha e bapisoa le placebo.63 Palo ea bakuli ba nang le ho mpefala e ne e le tlaase sehlopheng sa TEZSPIRE ho feta sehlopheng sa placebo ho pholletsa le linako tsohle tsa selemo.46

"Bongata ba bakuli ba nang le asthma e matla ba na le lintho tse ngata tse etsang hore motho a ruruhe, a bakoang ke ho kula, tšoaetso ea kokoana-hloko le baktheria, le tšilafalo ea moea, tseo kaofela li ka tlatsetsang ho mpefala ho tsoelang pele. Liphetho tsena tse ncha li totobatsa bokhoni ba TEZSPIRE ba ho fokotsa ho ata ho matla ha asthma ho bakuli ho sa tsotellehe maemo a biomarker le lintho tse bakang nako ea selemo, "ho boletse Dr. Jonathan Corren, setho sa lefapha la bongaka la David Geffen School of Medicine, UCLA, le mofuputsi ea ka sehloohong oa teko ea PATHWAY.

"Re thabetse ho tsoela pele ho bona bakuli ba nang le litlhaselo tse fokolang tsa asthma ka mor'a ho phekoloa ka TEZSPIRE ho itšetlehile ka liphello tsa litlhahlobo tsa morao-rao tsa liteko tsa NAVIGATOR le PATHWAY," ho boletse David M. Reese, MD, motlatsi oa motlatsi ea ka sehloohong oa Research and Development at Amgen. "Liphetho tsena li matlafatsa tumelo ea rona ea hore TEZSPIRE e na le monyetla oa ho ba moriana o fetolang batho ba nang le asthma e matla ho sa tsotelehe nako ea selemo kapa mofuta o itseng oa asthma e matla."

Liphetho tsena li hlahisoa Kopanong ea Selemo le Selemo ea 2022 American Academy of Allergy, Asthma & Immunology (AAAAI).

TEZSPIRE e amohetsoe United States bakeng sa phekolo ea asthma e matla 'me e tlas'a tlhahlobo ea taolo ho EU, Japane le linaheng tse ling tse' maloa ho pota lefatše.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Leave a Comment

Arolelana ho...